Skip to Content
Søg Menu

Forbedret standardbehandling ved myelomatose

I denne MEDtalk har Agoston Gyula Szabo udvalgt og perspektiverer en række studier, fra dette års ASH-kongres, der belyser, om standardbehandlingen af myelomatose kan forbedres.

Agoston Gyula Szabo

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video 6:39

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Fredrik Schjesvold

EHA23 Insights into the Changing Landscape of Myeloma Treatments

/ Fredrik Schjesvold
EHA23Myelomatose Play the Video 4:39
Sagar Lonial

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Sagar Lonial
ASCO23EHA23CAR-TMyelomatose Play the Video 02:20
Rakesh Popat

Integrating BCMA-Based Combination Regimens in Early R/R Multiple Myeloma

/ Rakesh Popat
EHA23Myelomatose Play the Video 03:23

High Expression of the Inhibitory Checkpoint Receptor TIGIT by CD8+ T-cells in Multiple Myeloma

/ Katrine Fladeland Iversen
MyelomatoseT-celler

Er risikoen for myelomatose geografisk betinget?

/ Lise Dueholm Bertelsen
Myelomatose
Paul Richardson

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Paul G. Richardson
ASH22Myelomatose Play the Video 2:58
Dr. Sagar Lonial

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Sagar Lonial
ASH22Myelomatose Play the Video 2:08
Back to top